Clinical Trials
3 trialsNCT07504458 2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3 Recruiting
NCT07296445 2025-12-29
LATITUDE
SDK Therapeutics, Inc.
Phase 3 Not yet recruiting
NCT00962767 2009-08-20
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 3 Completed